These data suggest that HER2 mRNA levels can be used as a biomarker of clinical benefit from trastuzumab, thus potentially discriminating between HER2‐addicted and HER2‐nonaddicted cases of HER2‐positive BC. The gene discussed is ERBB2; the disease is breast cancer.